Treatment with curative intent and survival in men with high-risk prostate cancer. A population-based study of 11 380 men with serum PSA level 20-100 ng/mL

BJU International

Volumn 111, Issue 3, 2013, Pages 381-388

  Ladjevardi, Sam ^a   Berglund, Anders ^a   Varenhorst, Eberhard ^b   Bratt, Ola ^c   Widmark, Anders ^d   Sandblom, Gabriel ^e  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

curative treatment; high risk tumours; palliative treatment; population based study; prostate cancer; prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER CURATIVE TREATMENT; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

AGED; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SWEDEN; TREATMENT OUTCOME;

EID: 84874667601     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11320.x     Document Type: Article

References (26)

1. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095-1101
2. Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 2009; 101: 1280-1283
3. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A., Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010; 46: 3040-3052
4. Varenhorst E, Garmo H, Holmberg L, et al. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival. Scand J Urol Nephrol 2005; 39: 117-123
5. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364: 1708-1717
6. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373: 301-308
7. Warde P, Mason M, Ding K,. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378: 2104-2111
8. Sobin LH, Gospodarowicz MK, Wittekind C, eds. International Union Against Cancer (UICC) TNM Classification of Malignant Tumors, 7th edn. Oxford: Wiley-Blackwell, 2009
9. Stattin P, Holmberg E, Johansson JE, et al. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010; 102: 950-958
10. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A., The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009; 24: 659-667
11. Adolfsson J, Garmo H, Varnehorst E, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007; 41: 456-477
12. Cause of Death Register. 2008. Available at: http://www.socialstyrelsen. se/publikationer2011/2011-7-6
13. Kastner C, Armitage J, Kimble A, Rawal J, Carter PG, Venn S,. The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting. Prostate Cancer Prostatic Dis 2006; 9: 270-274
14. Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M,. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol 2011; 185: 833-839
15. The Swedish Cancer Register. 2009. Available at: http://www. socialstyrelsen.se/publikationer2011/2011-12-15
16. Sandblom G, Holmberg L, Damberg JE, et al. Prostate-specific antigen as surrogate for characterizing prostate cancer subgroups. Scand J Urol Nephrol 2002; 36: 106-112
17. Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P,. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol 2011; 60: 554-563
18. Inman BA, Davies JD, Rangel LJ, et al. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. Cancer 2008; 113: 1544-1551
19. Van Hemelrijck M, Adolfsson J, Garmo H, et al. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol 2010; 11: 450-458
20. Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 2010; 28: 3448-3456
21. Verhagen PC, Schröder FH, Collette L, Bangma CH,. Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol 2010; 58: 261-269
22. Albertsen PC, Hanley JA, Gleason DF, Barry MJ,. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-980
23. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC,. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-565
24. Gontero P, Spahn M, Tombal B, et al. Is there a prostate-specific antigen upper limit for radical prostatectomy? BJU Int 2011; 108: 1093-1100
25. Engel J, Bastian PJ, Baur H, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010; 57: 754-761
26. Fall K, Strömberg F, Rosell J, Andrèn O, Varenhorst E, South-East Region Prostate Cancer Group. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol 2008; 42: 352-357